Annuncio • Jun 02

+ 2 more updates

Immatics Presents Clinical Activity and Response Dynamics of Anzu-Cel Prame Cell Therapy At 2026 Asco Annual Meeting

Immatics N.V. announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses. One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanoma. Anzu-cel showed a 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma. Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progression. Findings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in First Half 2027. As of September 24, 2025, 33 heavily pretreated patients with metastatic (stage IV) melanoma received a one-time infusion of anzu-cel at the recommended Phase 2 dose (RP2D, 1 - 10x10^9 TCR T cells) in the Phase 1b dose expansion. The treated patient population consisted of cutaneous melanoma (n=14), uveal melanoma (n=16), mucosal melanoma (n=2) and melanoma of unknown primary (n=1). All patients with cutaneous melanoma, mucosal melanoma and melanoma of unknown primary had metastatic stage IV disease including lesions in liver, brain and/or lung. All patients with uveal melanoma had metastatic stage IV disease with liver and/or extrahepatic metastases. Patients had a median of two prior lines of systemic treatment. The subgroup of patients with cutaneous melanoma (n=14) had a median of 2.5 lines of prior systemic treatments, including a median of two prior lines of immune checkpoint inhibitors. Of these, 64% (9/14) received a combination of ipilimumab and nivolumab and 29% (4/14) received a combination of nivolumab and relatlimab prior to anzu-cel infusion. Anzu-cel has maintained a manageable tolerability profile, which was consistent across patients with different melanoma subtypes. The most frequent treatment-emergent adverse events were anticipated cytopenias associated with lymphodepletion. Expected and manageable cytokine release syndrome (CRS) was mostly Grades 1 and 2, which is consistent with the mechanism of action. No patients experienced long-term CRS. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred infrequently, was manageable and mostly mild (Grades 1 and 2). Rapid, deep and durable anti-tumor activity of anzu-cel PRAME cell therapy, including durable responses up to greater than 3 years. cORR: 56% (18/32) for all melanoma, 50% (7/14) for cutaneous melanoma, 67% (10/15) for uveal melanoma. ORR: 64% (21/33) for all melanoma, 57% (8/14) for cutaneous melanoma, 69% (11/16) for uveal melanoma. DCR: 91% (30/33) for all melanoma, 93% (13/14) for cutaneous melanoma, 88% (14/16) for uveal melanoma. mDOR (range) /mFU [mo]: 14.6 (4.2, 38.2+) /18.7 for all melanoma, 17.9 (4.2, 38.2+) /18.7 for cutaneous melanoma, 11.0 (4.4, 31.6) /Not defined for uveal melanoma. mPFS (range) /mFU [mo]: 6.1 (1.4, 39.6+) /20.0 for all melanoma, 6.0 (1.4, 39.6+) /20.0 for cutaneous melanoma, 8.5 (1.4, 32.9) /10.4 for uveal melanoma. mOS (range) /mFU [mo]: 16.2 (2.4, 39.6+) /17.3 for all melanoma, 13.9 (2.4, 39.6+) /20.0 for cutaneous melanoma, Not reached (4.5, 34.2) /14.3 for uveal melanoma. The PFS rate was 55% at six months and 37% at 12 months. The overall survival rate was 70% at 12 months and 46% at 24 months. 42% (14/33) of patients experienced a deep response (greater than or equal to 50% tumor reduction). In these patients, mPFS was 15.9 months at 39.6 months mFU. Anzu-cel induced systemic anti-tumor activity across multiple metastatic sites, including difficult-to-treat metastases, such as liver, lung, lymph node, abdomen/peritoneum, skin and others. Even patients who had a best overall response of progressive disease (PD) according to RECIST 1.1 (n=3) experienced shrinkage of individual lesions. Progressive disease was frequently the result of new lesions, progression of non-target lesions, or selective outgrowths of individual lesions, while many target lesions remained controlled, indicating continued control of baseline disease. Responses occurred rapidly (median time to BOR: 1.4 months) and were durable across multiple metastatic sites, including target and non-target lesions. These findings support the continued development of anzu-cel in advanced melanoma. Immatics’ ongoing Phase 3 clinical trial, SUPRAME, is evaluating the efficacy, safety and tolerability of anzu-cel PRAME TCR T-cell therapy as a monotherapy vs. investigator's choice in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a PD-1 immune checkpoint inhibitor. In parallel, a Phase 2 cohort in metastatic uveal melanoma is ongoing and intended to support a potential label expansion for anzu-cel following expected initial approval in cutaneous melanoma. PRAME is a target expressed in more than 50 cancers. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. Anzu-cel (anzutresgene autoleucel; IMA203) is a PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01 on the cell surface and initiate a potent and specific anti-tumor response. Anzu-cel PRAME cell therapy is currently being evaluated in a registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” in patients with unresectable or metastatic cutaneous melanoma who have disease progression on or after treatment with at least one checkpoint inhibitor. In parallel, the Phase 1/2 clinical trial is ongoing with a focus on uveal melanoma.

Annuncio • Nov 09

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

Immatics N.V. announced interim data from the ongoing Phase 1 trial with ACTengine®? IMA203 in patients with recurrent and/or refractory solid cancers. The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2. Treatment with IMA203 GEN1 monotherapy in Phase 1a and Phase 1b Cohort A at RP2D demonstrated durable objective responses in melanoma patients with one patient exceeding 12 months and two patients exceeding 15 months post infusion and a 50% (6/12) confirmed objective response rate (cORR). In line with previous results, IMA203 GEN1 monotherapy was well tolerated at total doses up to 10x109 TCR-T cells infused. In addition, the first data on the company’s second-generation product candidate IMA203CD8 demonstrated 56% (5/9) cORR with enhanced pharmacology and a differentiated response pattern compared to IMA203 GEN1. The company plans to develop IMA203 GEN1 in melanoma and to pursue development of IMA203 in ovarian cancer, uterine cancer, NSCLC, triple-negative breast cancer and other tumor types preferentially with IMA203CD8 GEN2. The melanoma-focused data on IMA203 GEN1 will be presented by Martin Wermke, MD, Professor at the University Hospital Dresden and Coordinating Investigator of the ACTengine® IMA203 TCR-T trial, at the 20th International Congress of the Society for Melanoma Research in Philadelphia, PA, taking place November 6th-9th, 2023. IMA203 GEN1 in melanoma patients treated at RP2D: IMA203 GEN1 demonstrates a high rate of objective responses with ongoing durability of more than 15 months after treatment: At data cut-off on September 30, 2023, a total of 16 PRAME-positive patients with cutaneous, uveal or melanoma of unknown primary origin were infused with IMA203 GEN1 at the recommended Phase 2 dose (RP2D, 1-10x109 total TCR-T cells) across Phase 1a or Phase 1b Cohort A. IMA203 GEN1 monotherapy continues to be well tolerated. All 16 patients experienced cytopenia (Grade 1-4) associated with lymphodepletion as expected. Patients had mostly mild-moderate cytokine release syndrome (CRS), of which 10 patients (63%) had Grade 1, and 5 patients (31%) Grade 2 and 1 patient (6%) Grade 3 CRS. One non-serious, mild (Grade 1) immune effector cell associated neurotoxicity syndrome (ICANS) was observed. No dose-dependent increase of CRS, no dose-limiting toxicities (DLTs) and no IMA203-related death was observed. The safety profile for non-melanoma patients treated with IMA203 GEN1 was generally consistent with safety in the melanoma subset and is provided in the appendix of the presentation. 13 out of 16 infused patients were evaluable for efficacy analysis based on at least one tumor response assessment being available post treatment. These patients received a median total infused dose of 1.73x109 IMA203 TCR-T cells (range 1.07-5.12x109 TCR-T cells). Most patients were heavily pre-treated with a median of 4 lines of systemic therapies, thereof a median of 2 lines of checkpoint inhibitors; all 8 cutaneous melanoma patients were checkpoint inhibitor-refractory and 5 of 8 were BRAF inhibitor-pretreated. 50% (6/12) confirmed objective response rate (cORR) and 62% (8/13) initial ORR (RECIST 1.1). Durability of responses ongoing beyond 12 months in one patient and 15 months in two patients after treatment. Median duration of response (mDOR) was not reached (min 2.2+ months, max 14.7+ months) at a median follow-up (mFU) of 14.4 months. RP2D has been defined at 1-10x109 total TCR-T cells. Cell product manufacturing: 7-day manufacturing process plus 7-day release testing. Manufacturing success rate: >95% to reach RP2D. Immatics has recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for IMA203 GEN1 in multiple PRAME-expressing cancers, including cutaneous and uveal melanoma, and is now targeting a registration-enabling Phase 2 trial in cutaneous melanoma potentially bundled with uveal melanoma in 2024. Discussions with FDA to align on patient populations, trial design and CMC aspects concerning the planned Phase 2 trial are ongoing. IMA203CD8 GEN2 in Cohort C: First clinical data set on IMA203CD8 shows an enhanced pharmacology profile with a differentiated response pattern compared to IMA203 GEN1 At data cut-off on September 30, 2023, a total of 12 PRAME-positive patients were infused with IMA203CD8 GEN2 across DL3 (0.2-0.48x109 TCR-T cells/m2 BSA), DL4a (0.481-0.8x109 TCR-T cells/m2 BSA) and DL4b (0.801-1.2x109 TCR-T cells/m2) in Cohort C with a median total infused dose of 1.17x109 IMA203CD8 TCR-T cells (range 0.64-2.05x109 TCR-T cells). All patients were heavily pre-treated with a median of 3 lines of systemic therapies. All patients experienced cytopenia (Grade 1-4) associated with lymphodepletion as expected. 11 out of 12 patients (92%) experienced a cytokine release syndrome (CRS), of which 8 patients (67%) had Grade 1 or 2 CRS, 2 patients (17%) had Grade 3 CRS and 1 patient (8%) had a Grade 4 CRS. The latter patient also had a reported Grade 4 neurotoxicity. No ICANS or neurotoxicity was reported for the other patients. No IMA203CD8-related deaths were observed. Dose-limiting toxicities (DLTs) were reported for 2 of 4 patients treated at DL4b. No DLT was reported for all 4 patients treated at DL3, or all 4 patients treated at DL4a. DL4a dose cohort is ongoing. Initial clinical activity was observed with a cORR of 56% (5/9) and initial ORR of 58% (7/12) (RECIST 1.1). 6 of 7 responses (including two unconfirmed responses with no subsequent scan available at data cut-off) were ongoing at data cut-off with longest response at >12 months after infusion. mDOR was not reached (min 2.0+ months, max 11.5+ months) at a mFU of 4.8 months. Reduction of tumor size was observed in 11 out of 12 patients, with a deepening of response from initially stable disease (SD) to partial response (PR) observed in two patients. Translational data showed enhanced pharmacology of IMA203CD8 GEN2: trend towards responses at lower T cell dose and higher tumor burden compared to IMA203 GEN1; IMA203CD8 GEN2 achieved higher peak expansion (Cmax) when normalized to infused dose and T cells showed higher initial activation levels without exhaustion over time.

Biotechs Crescita del settore	17.04%
Tasso di crescita dei ricavi	-0.63%
Rendimento del capitale proprio	-51.69%
Margine netto	-495.27%
Ultimo aggiornamento sugli utili	30 Jun 2026

Data	Ricavi	Utili	Spese G+A	Spese di R&S
30 Jun 26	42	-207	55	0
31 Mar 26	37	-214	54	0
31 Dec 25	48	-196	51	0
30 Sep 25	85	-120	51	0
30 Jun 25	130	-74	50	-5
31 Mar 25	144	-22	47	0
31 Dec 24	156	15	46	0
30 Sep 24	116	-49	43	0
30 Jun 24	71	-74	41	-2
31 Mar 24	74	-77	40	0
31 Dec 23	54	-95	38	0
30 Sep 23	76	-84	38	0
30 Jun 23	85	-79	37	7
31 Mar 23	80	-68	36	0
31 Dec 22	173	28	36	0
30 Sep 22	151	34	35	0
30 Jun 22	142	28	35	0
31 Mar 22	130	15	35	0
31 Dec 21	35	-93	34	0
30 Sep 21	28	-95	34	0
30 Jun 21	30	-231	35	0
31 Mar 21	32	-226	36	0
31 Dec 20	31	-211	34	0
30 Sep 20	26	-208	30	0
30 Jun 20	23	-49	24	0
31 Mar 20	22	-34	16	0
31 Dec 19	18	-32	12	0
31 Dec 18	4	-31	8	0

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/09/13 15:48
Prezzo dell'azione a fine giornata	2026/09/11 00:00
Utili	2026/06/30
Utili annuali	2025/12/31

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
Alec Stranahan	BofA Global Research
Eric Schmidt	Cantor Fitzgerald & Co.
Yevgeniya Livshits	Chardan Capital Markets, LLC

Immatics Performance degli utili passati

Criteri Il passato verificati 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Recent updates

Immatics Launches $150 Million Offering Following Recent Share Price Decline

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $149.995686 million.

Immatics N.V. has filed a Follow-on Equity Offering in the amount of $149.995686 million.

Immatics Expects SUPRAME Phase 3 Anzu-cel Data in Early 2027 With BLA Filing Planned

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028

Immatics N.V., Annual General Meeting, Jun 18, 2026

Immatics Presents Clinical Activity and Response Dynamics of Anzu-Cel Prame Cell Therapy At 2026 Asco Annual Meeting

Immatics Reports Promising Response Rates for IMA203CD8 PRAME Cell Therapy in Solid Tumors

Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Immatics N.V. Highlights Prame-Directed Tcr T-Cell Therapy Inducing Remission In Pediatric Nephroblastoma Patient

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Immatics N.V. has filed a Follow-on Equity Offering.

Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Price target increased by 11% to US$16.29

Immatics N.V. Appoints Amie Krause as Chief People Officer, Effective October 27, 2025

Immatics Announces CFO Changes

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

Consensus revenue estimates fall by 18%

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Immatics N.V., Annual General Meeting, Jun 18, 2025

Immatics IMA203 PRame Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-Tumor Activity and Durability in Patients with Metastatic Melanoma

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Immatics N.V. Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-Cell Therapy At 2025 Asco Annual Meeting

Price target decreased by 8.7% to US$15.30

Consensus revenue estimates increase by 35%, EPS downgraded

Immatics N.V.: Trading Below Cash, But Not Without Reason

Full year 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Price target decreased by 8.8% to US$16.42

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million.

Immatics N.V. has filed a Follow-on Equity Offering.

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded